Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

類似資料

• Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non‐Asian patients with previously untreated diffuse large B‐cell lymphoma in POLARIX
  著者:: Michael Z. Liao, 等
  出版事項: (2023-12-01)
• Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
  著者:: Dan Lu, 等
  出版事項: (2020-01-01)
• Excellent Interim Treatment Response with Polatuzumab Vedotin
  著者:: Özgür Mehtap, 等
  出版事項: (2020-11-01)
• Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
  著者:: Christopher R. Flowers, 等
  出版事項: (2023-09-01)
• Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
  著者:: Randall C. Dere, 等
  出版事項: (2023-03-01)